2023
The radiologically isolated syndrome: revised diagnostic criteria
Lebrun-Frénay C, Okuda D, Siva A, Landes-Chateau C, Azevedo C, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud D, Casez O, Mathey G, de Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci O. The radiologically isolated syndrome: revised diagnostic criteria. Brain 2023, 146: 3431-3443. PMID: 36864688, PMCID: PMC11004931, DOI: 10.1093/brain/awad073.Peer-Reviewed Original ResearchMeSH KeywordsAdultDemyelinating DiseasesDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisRisk FactorsConceptsRadiologically isolated syndromeClinical eventsGroup 1Risk factorsDIS criteriaPresence of spinal cord lesionsClinical follow-up timeCSF-restricted oligoclonal bandsMultivariate Cox regression modelDiagnostic criteriaFocal T2 hyperintensitiesGadolinium-enhancing lesionsMultiple sclerosisNegative predictive valueFollow-up scansFollow-up timeArea under the curveClass I evidenceSpinal cord lesionsCox regression modelsRisk of developmentWhite matter lesionsProspective databaseSymptomatic MST2 lesions
2020
Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event
Lebrun‐Frenay C, Kantarci O, Siva A, Sormani M, Pelletier D, Okuda D, Azevedo C, Amato M, Bensa C, Berger E, Brochet B, Ciron J, Cohen M, Inglese M, Keegan B, Labauge P, Laplaud D, Le Page E, Louapre C, Makhani N, Mathey G, Mondot L, Montalban X, Pelletier J, Seze J, deStefano N, Thouvenot E, Tintore M, Tutuncuoglu M, Uygunoglu U, Vermersch P, Weinshenker B, Zeydan B. Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event. Annals Of Neurology 2020, 88: 407-417. PMID: 32500558, DOI: 10.1002/ana.25799.Peer-Reviewed Original ResearchConceptsFirst clinical eventSubsequent clinical eventsGadolinium-enhancing lesionsSpinal cord lesionsClinical eventsRIS subjectsCord lesionsIndependent predictorsMultivariate Cox regression modelMagnetic resonance imaging (MRI) characteristicsBaseline independent predictorsWorldwide cohort studiesPositive cerebrospinal fluidCox regression modelAnn NeurolIsolated SyndromeRIS diagnosisCohort studySymptom onsetMale sexMultiple sclerosisOligoclonal bandsInfratentorial lesionsMean ageClinical management
2013
Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS
Makhani N, Ngan BY, Kamath BM, Yeh EA. Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS. Neurology 2013, 81: 850-852. PMID: 23884038, PMCID: PMC3908464, DOI: 10.1212/wnl.0b013e3182a2cc4a.Peer-Reviewed Original Research
2009
Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL
Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL. Neurology 2009, 72: 2076-2082. PMID: 19439723, PMCID: PMC2923592, DOI: 10.1212/wnl.0b013e3181a8164c.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAge of OnsetChildCyclophosphamideDisease ProgressionDrug Administration ScheduleDrug ResistanceFemaleGlatiramer AcetateHumansImmunosuppression TherapyImmunosuppressive AgentsInterferon-betaMaleMitoxantroneMultiple SclerosisPeptidesRetrospective StudiesSecondary PreventionSex DistributionTreatment OutcomeConceptsMultiple sclerosisTreatment of childrenInduction therapyMaintenance therapyTreatment initiationDisability Status Scale scoreAggressive multiple sclerosisFirst-line therapyRetrospective chart reviewMajority of patientsStatus Scale scoreCyclophosphamide therapyChart reviewDisability scoresMost patientsMulticenter experienceMultiple relapsesRelapse ratePatient selectionTransient alopeciaBladder carcinomaTreatment administrationCyclophosphamideSide effectsScale score